A number of other analysts also recently weighed in on the stock. Wells Fargo & Co upgraded shares of Sientra from a market perform rating to an outperform rating and increased their price target for the company from $8.00 to $10.00 in a research report on Wednesday, June 5th. Zacks Investment Research upgraded Sientra from a sell rating to a hold rating in a research note on Wednesday, April 17th. BidaskClub upgraded Sientra from a strong sell rating to a sell rating in a research note on Thursday, April 25th. Finally, Craig Hallum decreased their price target on Sientra from $20.00 to $14.00 and set a buy rating for the company in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $20.00.
Shares of NASDAQ SIEN traded down $0.28 during midday trading on Thursday, reaching $5.52. The company’s stock had a trading volume of 983,100 shares, compared to its average volume of 849,553. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average price of $6.07. Sientra has a one year low of $4.78 and a one year high of $26.79. The stock has a market capitalization of $169.48 million, a P/E ratio of -1.70 and a beta of 0.29.
In other Sientra news, CFO Paul Sean Little purchased 17,391 shares of Sientra stock in a transaction dated Friday, June 7th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $99,998.25. Following the completion of the acquisition, the chief financial officer now owns 94,891 shares in the company, valued at approximately $545,623.25. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Keith J. Sullivan purchased 20,869 shares of Sientra stock in a transaction dated Friday, June 7th. The stock was acquired at an average price of $5.75 per share, for a total transaction of $119,996.75. Following the completion of the acquisition, the director now owns 203,141 shares of the company’s stock, valued at approximately $1,168,060.75. The disclosure for this purchase can be found here. Insiders own 13.30% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SIEN. BlackRock Inc. increased its stake in Sientra by 2.8% during the 4th quarter. BlackRock Inc. now owns 1,616,583 shares of the medical instruments supplier’s stock worth $20,546,000 after buying an additional 43,684 shares during the period. Granite Point Capital Management L.P. boosted its position in Sientra by 15.3% during the 2nd quarter. Granite Point Capital Management L.P. now owns 1,014,898 shares of the medical instruments supplier’s stock valued at $6,252,000 after acquiring an additional 134,898 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Sientra by 117.6% during the 4th quarter. Millennium Management LLC now owns 966,106 shares of the medical instruments supplier’s stock valued at $12,279,000 after purchasing an additional 522,153 shares during the last quarter. Stephens Inc. AR lifted its holdings in shares of Sientra by 81.1% during the 2nd quarter. Stephens Inc. AR now owns 254,832 shares of the medical instruments supplier’s stock valued at $1,570,000 after purchasing an additional 114,132 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Sientra by 10.0% during the 4th quarter. Geode Capital Management LLC now owns 254,747 shares of the medical instruments supplier’s stock valued at $3,237,000 after purchasing an additional 23,117 shares during the last quarter. Hedge funds and other institutional investors own 86.01% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: Why is the ROA ratio important?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.